| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00358982 Details | 2015-07-03 Interventional | 2 | 51 | Mocetinostat Hodgkin Disease Lymphoma Hodgkin's Lymph… | - - | |||
| NCT02091817 Details | 2015-07-02 Interventional | 1 | - | Oxytocin Prosopagnosia Congenital Pros… Healthy | We are currently engaged in other behavioral study. - | |||
| NCT01880307 2012-000645-13 2014-005702-37 Details | 2015-07-02 Interventional | 4 | 13 | Azathioprine Infliximab Prednisolone Crohn Disease Crohn's Disease | Not enough study subjects - | |||
| NCT01605942 Details | 2015-07-01 Interventional | 1 | 8 | Dexamethasone Cataract | Study terminated due to corporate decision. - | |||
| NCT00543582 Details | 2015-07-01 Interventional | 2 | 23 | Azacitidine Mocetinostat Lymphoma Lymphoma, Mantl… Lymphoma, Non-H… Hodgkin Lymphom… Non-Hodgkin Lym… | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.
All Celgene-sponsored trials with MGCD0103 will be closed. - | |||
| NCT00374296 Details | 2015-07-01 Interventional | 2 | 35 | Mocetinostat Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Myelogenous Leu… | The Clinical Development Program for MGCD0103 is being re-evaluated - | |||
| NCT02484768 Details | 2015-06-30 Interventional | 2 | 0 | Iron isomaltosi… Psychomotor Agi… Restless Legs S… Syndrome | as per GCP sponsor/company decision - | |||
| NCT00509834 Details | 2015-06-30 Interventional | 1/2 | 0 | Lactoferrin Candidemia Candidaemia | Patient population not available - | |||
| NCT00430469 2006-004012-52 Details | 2015-06-30 Interventional | 1/2 | 0 | Lactoferrin Bacterial Infec… Communicable Di… Infections Mycoses Bacterial Infec… Fungal Infectio… | Strategic company decision - | |||
| NCT01397630 Details | 2015-06-25 Interventional | 3 | 79 | Oxytocin Dystocia Labour Dystocia | Due to budgetary concerns, the TSC decided it best to adjust sample size as there was
sufficient data to assess feasibility. Recruitment was terminated early. - | |||
| NCT01231750 Details | 2015-06-25 Interventional | 3 | 7 | Capsaicin Angina Pectoris Angina, Stable Stable Angina | Unable to identify study population to achieve number expected - | |||
| NCT01016795 Details | 2015-06-25 Interventional | 2 | 32 | Lenograstim Lymphoma Malignant Lymph… | Study closed Nov 2000 by Amgen, who stopped drug delivery - | |||
| NCT00697060 Details | 2015-06-24 Interventional | 2 | 0 | Docetaxel Carcinoma, Non-… | Study cancelled prior to start due to change in company priorities. - | |||
| NCT00384566 Details | 2015-06-24 Interventional | 4 | 0 | Carvedilol Metoprolol Heart Failure Lung Diseases, … Pulmonary Disea… Chronic Obstruc… | In order to join forces with another study already running which aims to answer the same
question. - | |||
| NCT01830790 Details | 2015-06-23 Interventional | 2 | 10 | Sildenafil Citr… Macular Degener… Age-related Mac… | Inadequate support to complete recruitment/data analysis. Study was terminated early due to inadequate support to complete recruitment/data analysis. | |||
| NCT01175772 Details | 2015-06-23 Interventional | 2 | 6 | Celecoxib Cyclophosphamid… Methotrexate Carcinoma Carcinoma, Ovar… Ovarian Neoplas… Ovarian Carcino… | Due to change in the national policy of medications - | |||
| NCT01134926 Details | 2015-06-23 Interventional | 2 | 23 | Misoprostol Intra-uterine R… | The principal investigator left the organization - | |||
| NCT01009957 Details | 2015-06-23 Interventional | 2/3 | 71 | Everolimus MTOR Inhibitors Disease Progres… Kidney Diseases Polycystic Kidn… | After primary completition date, experimental drug was no longer available - | |||
| NCT00624182 Details | 2015-06-23 Interventional | 1 | - | Gemcitabine Bile Duct Neopl… Cholangiocarcin… Bile Duct Cance… | - - | |||
| NCT00543959 Details | 2015-06-23 Interventional | 2 | 346 | Pioglitazone Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… | This study is being discontinued based on data suggesting that none of the doses tested
demonstrated both glycemic & body fluid benefits vs. the comparitor - |